The 29th International Symposium on ALS/MND is being held in Glasgow, Scotland, UK on 7 – 9 December 2018.
See below for the programme of platform presentations. Please note that the programme is subject to change. Abstract numbers of each talk can be found at the end of each title (e.g., #C110). See the plenary speakers invited to this year's Symposium.

You can also download the print version of the programme here.

DAY 1 (Friday 7 December)

JOINT OPENING SESSION

09.00 - 09.10: Welcome to the 29th International Symposium on ALS/MND K Talbot and S Light (UK)

09.10 - 09.30: Revised Airlie House Consensus Guidelines for Design and Implementation of Amyotrophic Lateral Sclerosis (ALS) Clinical Trials based on the Modified Delphi Method H Mitsumoto (USA) #C1

09.30 - 09.40: Welcome on behalf of MND Scotland

09.40 - 09.50: International Alliance Humanitarian Award & International Alliance Forbes Norris Award

09.50 - 10.25: The microbiome, the immune system and brain function J Cryan (Ireland) #C2

10.25 - 10.45: IPG Award and winner's research presentation

SESSION 2: DEFINING ALS/MND

11.15 - 12.30: Defining ALS/MND: The Big Debate O Hardiman (Ireland), A Al-Chalabi (UK), M Kiernan (Australia), R Miller (USA) #C3 

SESSION 3A
STEM CELL MODELS

14.00 - 14.15: Cloning, stem cells and regenerative medicine I Wilmut (UK)

14.15 - 14.45: Modelling ALS using induced pluripotent stem cells combined with organ on chip technology C Svendsen (USA) #C4

14.45 - 15.00:  FM19G11 preserves blood brain barrier integrity and limits P-gP overexpression by reducing astrocytes toxicity in a human-derived in vitro cell model of familial and sporadic amyotrophic lateral sclerosis S Bonanno (Italy) #C5

15.00 - 15.15: Dysregulation of GluA1 Ca2+-permeable AMPAR in ALS – A potential converging pathomechanism causing motor neuron vulnerability to excitotoxicity B Selvaraj (UK) #C6

15.15 - 15.30: C9orf72 and TDP-43 iPS-derived motor neurons show alterations in calcium buffering through different mechanisms R Dafinca (UK) #C7 

SESSION 3B
INFORMATION, AUTONOMY AND DECISION MAKING

14.00 - 14.30: Gene testing for all? Supporting patient decisions in the post-genomic era C Shaw (UK) #C8

14.30 - 14.50: Developing a framework for the diagnostic interpretation of ALS genomes  D Leighton (UK) #C9 

14.50 - 15.10: Advance care planning in ALS: Representation and realisation of individual treatment goals through care management schemes S Spittel (Germany) #C10 

15.10 - 15.30: Decision support tools for motor neurone disease multidisciplinary care A Hogden (Australia) #C11 

SESSION 3C
NEUROIMAGING

14.00 - 14.20: Lifetime sport practice and brain metabolism in ALS: a [18F] FDG-PET study A Calvo (Italy) #C12

14.20 - 14.40: [11C] PBR28 PET imaging for characterizing spinal cord glial activation in ALS S Babu (USA) #C13 

14.40 - 15.00: Primary lateral sclerosis: part of the MND spectrum or disease entity? A multiparametric neuroimaging study with comprehensive clinical and genetic profiling E Finegan (Ireland) #C14 

15.00 - 15.20: Quantifying the post mortem ALS brain using ultra high-field MRI B Tendler (UK) #C15 

SESSION 4A
CELL BIOLOGY AND PATHOLOGY

16.00 - 16.30: The role of synapses in neurodegeneration T Spires-Jones (UK) #C16

16.30 - 17.00: Single Cell Biology as a tool to explore neurodevelopment and neurodegeneration L Goff (USA) #C17

17.00 - 17.15: The interactome of human TDP-43 in a cellular model of ALS E Feneberg (UK) #C18

17.15 - 17.30: Small non-coding RNAs generated by the ALS-associated ribonuclease angiogenin deliver novel and accessible biomarkers of disease progression in ALS M Hogg (Ireland) #C19

SESSION 4B
CLINICAL TRIALS AND TRIAL DESIGN

16.00 - 16.30: Improving outcomes as rapidly as possible for patients: Multi-arm, multi-stage platform, umbrella and basket protocols M Parmar (UK) #C20

16.30 - 16.50: Hurdles for pharmacogenetic interactions in ALS clinical trials: a post-hoc analysis and simulation study R van Eijk (Netherlands) #C21

16.50 - 17.10: Novel composite endpoint (NCE) extended analysis during double-blind-DB-and open-label extension-OLE-epochs [12 months] of Ibudilast phase 1A/2B clinical trial, rather than short-term responder analysis during DB-epoch [6 months], better predicts post wash out (PWO) survival B Brooks (USA) #C22

17.10 - 17.30: Randomized phase 2B trial of NP001, a novel immune regulator, in ALS R Miller (USA) #C23

SESSION 4C
NEUROPATHOLOGY

16.00 - 16.20: Selective vulnerability of the primary motor cortex in ALS M Nolan (UK) #C24

16.20 - 16.40: Upper motor neurons with TDP pathology from different species display similar cellular dysfunctions H Ozdinler (USA) #C25

16.40 - 17.00: Distinct TDP-43 inclusions suggest divergent pathomechanisms in FTLD and FTLD-ALS R Tan (Australia) #C26

17.00-17.20: Cognitive deficits in ALS are a marker of localized TDP-43 cerebral pathology J Gregory (UK) #C27


POSTER SESSION A

17.45 - 19.30


 

DAY 2 (Saturday 8 December)

SESSION 5A
AXONAL DEGENERATION

08.30 - 09.00: Mechanisms of axon degeneration and their relevance to ALS/MND M Coleman (UK) #C28

09.00 - 09.30: Axonal transport as a therapeutic target G Schiavo (UK) #C29

09.30 - 09.45: Neurotrophic factor-mediated regulation of axonal transport is impaired in SOD1 G93A mice A Tosolini (UK) #C30

09.45 - 10.00: Axon loss and microglial activation in the corticospinal tract in sporadic ALS patients with predominant upper motor neuron symptoms F Song (USA) #C31

SESSION 5B
TECHNOLOGY AND ALS/MND

08.30 - 08.50: Computer assessment of speech in a successful ALS treatment trial R Smith (USA) #C32

08.50- 09.10: Remote pulmonary function testing in ALS telemedicine A Geronimo (USA) #C33

09.10 - 09.30: Accelerometry for remote monitoring of disease progression in ALS clinical trials R van Eijk (Netherlands) #C34

09.30 - 09.45: ALS patients can measure their own function at home: Reliability, tolerability and relationships between outcomes J Shefner (USA) #C35

09.45 - 10.00: Preserving identity: The Speak:Unique voice banking pilot P Rewaj (UK) #C36

 

SESSION 5C
EPIDEMIOLOGY

08.30 - 08.50: Euro-MOTOR: a multicentre population-based case-control study of pre-existing medical conditions as risk factors for ALS S Peters (Netherlands) #C37

08.50 - 09.10: Causal effects of presymptomatic lifestyle on ALS, stratified by C9orf72 genotype H-J Westeneng (Netherlands) #C38

09.10 - 09.30: Are ALS motor phenotypes stochastic? A population-based case-control study A Chio (Italy) #C39

09.30 - 09.45: Is psychological stress a predisposing factor for ALS? An online international case-control study of premorbid stressful life events, resilience and anxiety J Parkin Kullmann (Australia) #C40

09.45 - 10.00: A family history of depression and anxiety predicts cognitive and behavioural changes in MND C McHutchison (UK) #C41

 

SESSION 6A
GENETICS AND GENOMICS

10.30 - 10.50: Genomic structural variation in ALS: A case-control study using 6579 whole genome sequences A Al Khleifat (UK) #C42

10.50 - 11.10: Identification of missing genetic association within non-coding elements using an artificial neural network J Cooper-Knock (UK) #C43

11.10 - 11.30: A precision genomics approach to dissect the pathogenesis of ALS/MND J Rubio (Australia) #C44

11.30 - 11.50: Discovery and characterisation of a novel genetic variant of amyotrophic lateral sclerosis T Moll (UK) #C45

11.50 - 12.10: Expression levels of C9ORF72 associate with survival after onset in C9ORF72-linked diseases M van Blitterswijk (USA) #C46

12.10 - 12.30: Spatial transcriptomics reveals spatially dysregulated expression of GRM3and USP47in amyotrophic lateral sclerosis J Gregory (UK) #C47

SESSION 6B
CLINICAL SUPPORT AND QUALITY OF LIFE

10.30 - 10.50: Patient Reported Outcomes Measures (PROMs) in Amyotrophic Lateral Sclerosis (ALS) F De Marchi (USA) #C48

10.50 - 11.10: Understanding quality of life in ALS/MND by modelling patient-reported outcomes C Young (UK) #C49

11.10 - 11.30: Jumping between the cracks: Attempting to navigate the world of care in motor neurone disease, a qualitative study E Hobson (UK) #C50

11.30 - 11.50: An online mindfulness intervention for people with ALS F Pagnini (Italy) #C51

11.50 - 12.10: Investigating protective factors of psychological distress in motor neuron disease (MND) caregivers S Carney (Ireland) #C52

12.10 - 12.30: Apathy subtypes, quality of life, wellbeing and caregiver burden in motor neurone disease R Radakovic (UK) #C53

 

SESSION 6C
PRODROMAL AND EARLY DISEASE MARKERS

10.30 - 10.50: Relative thalamic hypometabolism as an early marker of C9orf72 pathology J De Vocht (Belgium) #C54

10.50 - 11.10: Baseline and longitudinal volumetric changes associated with presymptomatic C9orf72 repeat expansion carriers C McMillan (USA) #C55

11.10 - 11.30: Early and distinct perfusion alterations in presymptomatic C9orf72, MAPT and GRN mutation carriers P Ferraro (USA) #C56

11.30 - 11.50: When does ALS begin? Insights from serum and CSF neurofilaments light and heavy M Benatar (USA) #C57

11.50 - 12.10: Phosphorylated neurofilament heavy chains (pNfH) in blood as an early diagnostic and prognostic biomarker in ALS K Poesen (Belgium) #C58

12.10 - 12.30: Peripheral immune biomarkers and the risk of neurodegenerative diseases in the Swedish AMORIS study S Yazdani (Sweden) #C59

 

SESSION 7A
NON-NEURONAL CELLS

14.00 - 14.30: Function and dysfunction of innate immune genes in microglia: implications for neurodegenerative disease  P St George-Hyslop (UK) #C60

14.30 - 14.50: Pathological study of glial inflammation in clinically pre-symptomatic spinal cords in patients with sporadic amyotrophic lateral sclerosis S Hayashi (Japan) #C61

14.50 - 15.10: Exosomes derived from bone marrow mesenchymal stem cells and their shuttled miRNAs remodel astrocytes isolated from adult SOD1G93A mice from a neurotoxic to a neuroprotective phenotype G Bonanno (Italy) #C62

15.10 - 15.30: C9orf72 expansion in astrocytes causes loss of metabolic flexibility, metabolic transport defects and loss of glycogen metabolism leading to increased toxicity under metabolic stress S Allen (UK) #C63

SESSION 7B
COGNITIVE AND PSYCHOLOGICAL CHANGE

14.00 - 14.30: The ALS-FTD spectrum: Diagnosis and management J Hodges (Australia) #C64

14.30 - 14.50: Cognition and behaviour does decline across the ALS disease course after controlling for attrition C Crockford (UK) #C65

14.50 - 15.10: Clinical correlates of memory decline in motor neuron disease J Machts (Germany) #C66

15.10 - 15.30: Unravelling psychosis in motor neurone disease: A study of clinical features, cognition, and survival E Devenney (Australia) #C67

 

SESSION 7C
NEUROPHYSIOLOGY

14.00 - 14.30: Beyond molecules: Could circuit pathophysiology contribute to pathology of motor neuron diseases? R Brownstone (UK) #C68

14.30 - 14.50: Excitability of spinal motoneurons in patients with ALS V Marchand-Pauvert (France) #C69

14.50 - 15.10: Implementing Motor Unit Number Index (MUNIX) in a large clinical trial: Real world experience from 27 centres C Neuwirth (Switzerland)  #C70

15.10 - 15.30: Dysfunction of attention switching networks in amyotrophic lateral sclerosis correlates to impaired cognitive flexibility R McMackin (Ireland)  #C71

 

SESSION 8A
PRECLINICAL THERAPEUTIC STRATEGIES

16.00 - 16.15: WVE-3972-01, an investigational stereopure antisense oligonucleotide for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) Zhong Zhong (USA) #C72

16.15 - 16.30: Antibody therapy targeting RAN proteins rescues ALS/FTD in C9orf72 BAC mice L Ranum (USA) #C73

16.30 - 16.45: In vivo delivery of single chain antibodies to target TDP-43 proteinopathy S Pozzi (Canada) #C74

16.45 - 17.00: Robust SOD1 knockdown in large mammal spinal cord using a novel delivery paradigm with AAV gene therapy targeting SOD1 for the treatment of SOD1-ALS H Patzke (USA) #C75

17.00 - 17.15: HTL0014242 a novel metabotropic glutamate receptor type 5 (mGlu5) negative allosteric modulator limits glial activation and slows late stage disease progression in the SOD1G93A mouse model of MND H Brown-Wright (UK) #C76

17.15 - 17.30: Protective action of CuII(atsm) in models of ALS is mediated through copper-dependent upregulation of astrocytic Nrf2  J Liddell (Australia) #C77

SESSION 8B
CLINICAL PROGRESSION

16.00 - 16.20: ALS onset in old people: Clinical features and prognosis M De Carvalho (Portugal) #C78

16.20 - 16.40: Primary lateral sclerosis (PLS)-specific PLSFRS reveals significant clinical changes over time in patients with PLS H Mitsumoto (USA) #C79

16.40 - 17.00: Phenotype-genotype characterisation of ‘long survivors’ with motor neurone disease in Scotland D Leighton (UK) #C80

17.00 - 17.15: Modelling individual amyotrophic lateral sclerosis disease courses in different centers using the D50 progression model J Grosskreutz (Germany) #C81

17.15 - 17.30: An examination of riluzole effect on transitions from stage to stage in the PRO-ACT cohort N Thakore (USA) #C82

SESSION 8C
TISSUE BIOMARKERS

16.00 - 16.15: Neuroendocrine and metabolic biomarkers in amyotrophic lateral sclerosis and frontotemporal dementia R Ahmed (Australia) #C83

16.15 - 16.30: Distinct features of plasma extracellular vesicles in amyotrophic lateral sclerosis patients V Bonetto (Italy) #C84

16.30 - 16.45: Plasma extracellular vesicle microRNA expression in ALS patients from the National ALS Registry D Re (USA) #C85

16.45 - 17.00: Identification of a non-coding RNA biomarker signature from serum in ALS G Joilin (UK) #C86

17.00 - 17.15: A combination of ferroptosis-based biomarkers improves the prediction of functional decline in ALS patients P-F Pradat (France) #C87

17.15 - 17.30: Novel function of neuronal apoptosis inhibitory protein: implication for a risk factor and a prognostic marker in ALS O Kano (Japan) #C88

 


POSTER SESSION B

17.45 - 19.30


 

DAY 3 (Sunday 9 December)

SESSION 9A
DISEASE MODELS

08.30 - 09.00: Identification of a pro-apoptotic signalling cascade in FTD-ALS models S Sweeney (UK) #C89

09.00 - 09.20: C9orf72 arginine-rich dipeptide proteins interact with ribosomal proteins in vivo to induce a toxic translational arrest that is rescued by eIF1A T Moens (UK) #C90

09.20 - 09.40: ALS/FTD associated C9orf72 expansions activate the heat shock response and induce SOD1 proteinopathy T Ramesh (UK) #C91

09.40 - 10.00: BMAA, a cyanobacterial neurotoxin, triggers neurodegenerative changes in motor neurons and microglial activation in the spinal cord D Davis (USA) #C92

SESSION 9B
END OF LIFE DECISIONS

08.30 - 08.50: Wishes for hastened death in ALS: How should we as clinicians respond? G Borasio (Switzerland) #C93

08.50 - 09.10: MAiD in Canada: Legalization of medical assistance in dying has changed the discussion of WTHD in ALS W Johnston (Canada) #C94

09.10 - 09.30: Wishes for hastened death in ALS in Japan: The need for culture-sensitive answers M Ogino (Japan) #C95

09.30 - 10.00: PANEL DISCUSSION

 

SESSION 10A
RNA AND PROTEIN PROCESSING

10.30 - 11.00: Connection between nucleocytoplasmic transport and protein aggregation in ALS D Dormann (Germany) #C96

11.00 - 11.20: Synergistic interaction between low complexity domains in FUS is important for toxicity in drosophila and for liquid-liquid phase separation L Van Den Bosch (Belgium) #C97

11.20 - 11.40: Mechanisms of paraspeckle hyper-assembly in ALS T Shelkovnikova (UK) #C98

11.40 - 12.00: Mouse TDP-43 C-terminal mutations lead to an ALS-like phenotype and splicing gain of function producing novel splicing events, skiptic exons P Fratta (UK) #C99

12.00 - 12.20: Optogenetic enhancement of TDP-43 intermolecular interaction triggers its cytoplasmic mislocalization and inhibits axon outgrowth of spinal motor neurons K Asakawa (Japan) #C100

12.20 - 12.40: Optogenetic modulation of TDP-43 proteinopathy C Donnelly (USA) #C101

SESSION 10B
RESPIRATORY AND NUTRITIONAL SUPPORT

10.30 - 10.50: Gastrostomy, rates of decline of ALSFRS-R subscores and BMI, and survival N Thakore (USA) #C102

10.50 - 11.10: Measuring rate of decline in pulmonary function in ALS: Results from the ALS Nutrition/NIPPV Study Group C Jackson (USA) #C103

11.10 - 11.30: Slow vital capacity and functional decay in ALS S Pinto (Portugal) #C104

11.30 - 11.50: Enhancing the efficacy of non-invasive ventilation for patients with motor neurone disease: A systematic review and multicentre survey D O'Brien (UK) #C105

11.50 - 12.10: Impact of a combined expiratory and inspiratory respiratory strength training program in ALS: Results of a randomized sham controlled trial E Plowman (USA) #C106

12.10 - 12.30: Survival and outcomes of 122 patients with ALS/MND using tracheostomy ventilation (TV) P Cazzolli (USA) #C107

JOINT CLOSING SESSION

13.30 - 14.00: Energy metabolism defects in ALS L Dupuis (France) #C108

14.00 - 14.30: Fitness, exercise and ALS P Shaw (UK) #C109

14.30 - 14.40: Patient Impact Award

14.40 - 14.50: Poster Prize

14.50 - 15.00: Invitation to Perth 2019

15.00 - 15.15: Late breaking news


Symposium Programme Committee

Kevin Talbot (Chair of Programme Committee), Professor of Motor Neuron Biology, University of Oxford

Siddharthan Chandran (Chair of Clinical and management meeting), Professor of Neurology, University of Edinburgh

Gareth Miles (Chair of Biomedical research meeting), Professor of Neuroscience,  University of St Andrews

Steve Bell, Deputy Director of Care, Motor Neurone Disease Association

Nick Cole, Head of Research, Motor Neurone Disease Association

Brian Dickie, Director of Research Development, Motor Neurone Disease Association

Richard Ribchester, Professor of Cellular Neuroscience, Euan MacDonald Centre for MND Research

Jeffrey Rosenfeld, Professor of Neurology, Loma Linda University

Carolyn Young, Consultant Neurologist, The Walton Centre